Clinical Development Containment Generic Pharmaceutical Trials 
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.
The Pharma Data
MAY 2, 2021
Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 2, 2023
It contains the antiviral medications nirmatrelvir and ritonavir. This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Toujeo generated Sanofi €1.12 Pfizer’s total global revenue from Paxlovid was $18.93 billion ($1.17
The Pharma Data
DECEMBER 23, 2020
24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .
The Pharma Data
DECEMBER 23, 2020
Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Under the signed license agreement, Aurobindo Pharma has obtained the exclusive rights to commercialize in India and to UNICEF and non-exclusive rights in other select emerging and developing markets.
Expert insights. Personalized for you.
52 
Let's personalize your content